TABLE 1.

Immunotherapeutic Agents in Clinical Development for the Treatment of Advanced Non–Small Cell Lung Cancer

Agent	Description
Checkpoint Inhibitors
Nivolumab	Fully human IgG4 monoclonal antibody directed against PD-1 on T cells
Pembrolizumab (MK-3475)	Humanized IgG4 monoclonal antibody directed against PD-1 on T cells
BMS-936559	Fully human IgG4 monoclonal antibody directed against PD-L1 on tumor cells
MPDL3280A	Human IgG1 monoclonal antibody directed against PD-L1 on tumor cells
MEDI4736	Fully human IgG1 monoclonal antibody directed against PD-L1 on tumor cells
Ipilimumab	Fully human IgG1 monoclonal antibody directed against CTLA-4 on T cells
Lirilumab (IPH2102)	Fully human monoclonal antibody directed against the killer-cell immunoglobulin-like receptor on NK cells
BMS-986016	Monoclonal antibody directed against the lymphocyte-activation gene 3 on tumor infiltrating lymphocytes
Vaccines
Tecemotide (liposomal BLP25)	Vaccine composed of the exposed core peptide of MUC-1
Racotumomab	Patient idiotype-specific vaccine against NGg GM3
TG4010	Vaccine that uses a recombinant vaccinia virus (modified virus of Ankara) that encodes for human MUC-1 and IL-2
Nonspecific Immune Stimulator
Talactoferrin alfa	Recombinant human lactoferrin

CTLA-4, cytotoxic T lymphocyte antigen-4; IgG, immunoglobulin G; IL-2, interleukin-2; MUC-1, mucin 1; NGg, N-glycolil; NK, natural killer; NSCLC, non–small cell lung cancer; PD-1, programmed death-1; PD-L1, programmed death ligand-1